3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, B-Cell
9
Lymphoma, Non-Hodgkin
7
Recurrence
6
Multiple Myeloma
4
Leukemia, Myeloid, Acute
4
Lymphoma, Mantle-Cell
3
Lymphoma
3
Burkitt Lymphoma
3
Lymphoma, Follicular
2
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Platinum-Resistant Ovarian Carcinoma
1
Plasmacytoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Lymphoma, B-Cell, Marginal Zone
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
Immunotherapy, Adoptive
×
Clear all
NCT07280494
2025-12-12
S101MRD
Peking University People's Hospital
Phase 1
Recruiting
18 enrolled